Advanced Filters
noise

Charlestown, Massachusetts Clinical Trials

A listing of Charlestown, Massachusetts clinical trials actively recruiting patient volunteers.

Found 1,870 clinical trials
K Kyle Potter, MD

A Novel Approach to Upper Extremity Amputation to Augment Volitional Control and Restore Proprioception

The hypothesis of this research protocol is that the investigators will be able to redesign the manner in which upper limb amputations are performed so as to enable volitional control of next generation prosthetic devices and restore sensation and proprioception to the amputated limb. The investigators will test this hypothesis …

18 - 65 years of age All Phase N/A
A Alekhya Nanduri

Comparison of Methods of Pulmonary Blood Flow Augmentation in Neonates: Shunt Versus Stent (The COMPASS Trial)

COMPASS is a prospective multicenter randomized interventional trial. Participants with ductal-dependent pulmonary blood flow will be randomized to receive either a systemic-to-pulmonary artery shunt or ductal artery stent. Block randomization will be performed by center and by single vs. two ventricle status. Participants will be followed through the first year …

1 - 30 years of age All Phase N/A
D Danielle Wallace, MD

Epcoritamab and Rituximab for First-line Follicular Lymphoma

The purpose of this study is to determine how effective and safe the combination of rituximab and epcoritamab is in treating patients with Follicular Lymphoma (FL) and who have not received other treatments for their lymphoma. The names of the study drugs involved in this study are: Rituximab (a type …

18 years of age All Phase 2
M Miracle Johnson

Low Sodium Oxybate in Patients With Idiopathic Hypersomnia

Low sodium oxybate has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic hypersomnia. In this study, the researchers want to learn how low sodium oxybate impacts ability of people diagnosed with idiopathic hypersomnia to sleep for long periods of time. In addition, this …

18 - 65 years of age All Phase 4
L Lael Yonker, MD

AT1001 for the Treatment of Long COVID

The primary objective of this study is to evaluate the safety and efficacy of Larazotide (AT1001) versus placebo in children and young adults 7 to ≤21 years of age who present with symptoms of Long COVID in the presence of SARS-CoV-2 antigenemia. AT1001 (n=32) or placebo (n=16) will be administered …

7 - 21 years of age All Phase 2
A Andy Bolender

Mapping Auricular Vagus Nerve Circuitry

This study will determine how noninvasive nerve stimulation affects human brain, stomach, and autonomic activity.

18 - 65 years of age All Phase N/A
T Tatiana Falcone, M.D.

Ketamine Treatment of Youth Suicide Attempters

Ketamine, an NMDA antagonist, has been shown to have rapid anti- suicidal effects. However, its safety and efficacy and special populations has not been investigated and documented. Several reports in adults suggest rapid decrease of suicidal ideation. In the last decade there is an alarming increase of the number of …

14 - 30 years of age All Phase 3
K Kristina Simonyan, MD, PhD

Brain-Computer Interfaces in Laryngeal Dystonia

The researchers will develop and evaluate the use of adaptive closed-loop brain-computer interface therapeutic intervention in laryngeal dystonia.

18 - 80 years of age All Phase N/A
S Sharmila Dorbala, MBBS, MPH

Ultrasound Therapy In Cardiac Amyloidosis

This is a prospective pilot clinical study of subjects with cardiac amyloidosis and control subjects without amyloidosis where we plan to evaluate changes in myocardial blood flow, systolic and diastolic function before and after sonotherapy.

18 - 90 years of age All Phase 4
E Elizabeth A Lawson, MD

Oxytocin for Weight Loss in Adolescents

This is a randomized, double blind, placebo-controlled study of the effects of intranasal oxytocin in youths with obesity, ages 12-18 years old. Subjects will be randomized to receive intranasal oxytocin or placebo (3 sprays per nostril, 4 times per day) for 12 weeks. Study visits include screening to determine eligibility, …

12 - 18 years of age All Phase 2

Simplify language using AI